Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension

Review

(2545) Views  (691) Full article downloads

Authors: Amber Lundy, Nahla Lutfi, Cherylyn Beckey

Published Date May 2009 Volume 2009:5 Pages 429 - 440

DOI: http://dx.doi.org/10.2147/VHRM.S3066

Amber Lundy, Nahla Lutfi, Cherylyn Beckey

Veterans Affairs Medical Center, Pharmacy Service, West Palm Beach, FL, USA

Abstract: Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent. In the 1990s, several meta-analyses and a case-control study were published which raised concern regarding increased mortality and increased risk for myocardial infarction with short-acting nifedipine. Further evaluation of these meta-analyses and case control study underscores some important limitations and the need to further elucidate the role of this class of medications in high-risk patients. Until 2000, there was a paucity of data on the long-term effects as well as the long-term outcomes of CCBs in the treatment of stable coronary disease or in patients with manifestations of the disease such as hypertension or angina. While it has been well established that nifedipine and other dihydropyridines lower blood pressure and improve symptoms of angina, several studies were designed to evaluate the effect of dihydropyridines on “hard” outcomes, specifically cardiovascular and cerebrovascular events. In this review, we describe the clinical studies evaluating the use of nifedipine when compared to placebo as well as other anti-hypertensive therapies in an attempt to identify the most appropriate place in therapy for this class of medications and to further clarify its utilization in high-risk patients.

Keywords: nifedipine, dihydropyridine, ACTION, calcium-channel blocker, coronary heart disease, hypertension

Readers of this article also read: